Disclosed is the use of an antisense oligonucleotide inhibitor of miR-499 and an antisense oligonucleotide inhibitor of miR-208b or miR-208 for preparation of a medicament for treating pathologic cardiac hypertrophy, heart failure, or myocardial infarction in a subject in need thereof, wherein the antisense oligonucleotide inhibitor of miR-499 comprises a sequence that is at least partially complementary to a miR-499 sequence, and wherein the antisense oligonucleotide inhibitor of miR-208b or miR-208 comprises a sequence that is at least partially complementary to a miR-208b or miR-208 sequence. Further disclosed is the use of an antisense oligonucleotide inhibitor of miR-499 and an antisense oligonucleotide inhibitor of miR-208b or miR-208 for preparation of a medicament for preventing pathologic cardiac hypertrophy or heart failure in a subject in need thereof, wherein the antisense oligonucleotide inhibitor of miR-499 comprises a sequence that is at least partially complementary to a miR-499 sequence, and wherein the antisense oligonucleotide inhibitor of miR-208b or miR-208 comprises a sequence that is at least partially complementary to a miR-208b or miR-208 sequence, and wherein the subject is at risk of developing pathologic cardiac hypertrophy or heart failure.
